Erasca, Inc. (ERAS) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 33.57M USD | Liabilities, Current |
| Cash and equivalents | 42.54M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 226.20M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $33.57M | $42.54M | $226.20M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $26.66M | $47.26M | $196.53M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $28.51M | $73.81M | $202.27M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $28.71M | $70.23M | $218.17M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $28.15M | $66.14M | $234.52M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $25.47M | $70.48M | $234.10M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $31.39M | $67.74M | $230.57M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $30.02M | $68.89M | $250.03M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $24.89M | $172.80M | $235.61M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $30.24M | $76.73M | $220.96M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $26.16M | $93.08M | $219.28M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $26.73M | $112.86M | $183.81M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $23.29M | $138.79M | $178.46M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $25.52M | $272.76M | $116.98M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $48.69M | $284.22M | $151.40M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $27.68M | $219.26M | $136.67M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $22.32M | $298.01M | $73.47M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $21.39M | $333.35M | $59.19M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $26.38M | $360.49M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $19.59M | $445.81M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $17.91M | $156.40M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $169.99M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $13.68M | $65.38M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $62.02M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $104.34M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |